Chemotherapy Research - Cancer treatment, Side effects, drugs

Chemotherapy Research Today is a free monthly online journal that collates and summarizes the latest research about Chemotherapy, including details on cancer treatment, side effects, drugs.


Chemotherapy Research Today

Home

View Latest Issue

Information About Chemotherapy

Books on Chemotherapy

Advertising in Research Today

View Other Research Today Publications



Volume 2 (2005), Issue 12 (December)

  1. Risk of death in elderly users of conventional vs. atypical antipsychotic medications.
    N Engl J Med, 353(22): 2335-41. [Abstract] [Full-text]
  2. Electronic surveillance system for monitoring surgical antimicrobial prophylaxis.
    Pediatrics, 116(6): 1317-22. [Abstract] [Full-text]
  3. Using a preprinted order sheet to reduce prescription errors in a pediatric emergency department: a randomized, controlled trial.
    Pediatrics, 116(6): 1299-302. [Abstract] [Full-text]
  4. Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study.
    Lancet Oncol, 6(12): 945-52. [Abstract] [Full-text]
  5. Site-specific drug delivery by photochemical internalization enhances the antitumor effect of bleomycin.
    Clin Cancer Res, 11(23): 8476-85. [Abstract] [Full-text]
  6. Phase I study of low-dose interleukin-2, fludarabine, and cyclophosphamide for previously untreated indolent lymphoma and chronic lymphocytic leukemia.
    Clin Cancer Res, 11(23): 8413-7. [Abstract] [Full-text]
  7. Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias.
    Clin Cancer Res, 11(23): 8403-12. [Abstract] [Full-text]
  8. The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer.
    Clin Cancer Res, 11(23): 8398-402. [Abstract] [Full-text]
  9. Identification of a novel estrogen-regulated gene, EIG121, induced by hormone replacement therapy and differentially expressed in type I and type II endometrial cancer.
    Clin Cancer Res, 11(23): 8258-64. [Abstract] [Full-text]
  10. Photodynamic therapy for focal retinal pigment epithelial leaks secondary to central serous chorioretinopathy.
    Ophthalmology, 112(12): 2088-94. [Abstract] [Full-text]
  11. Time course and morphology of vascular effects associated with photodynamic therapy.
    Ophthalmology, 112(12): 2061-9. [Abstract] [Full-text]
  12. Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial.
    Lancet, 366(9501): 1935-44. [Abstract] [Full-text]
  13. Comparison of early retreatment with the standard regimen in verteporfin therapy of neovascular age-related macular degeneration.
    Ophthalmology, 112(12): 2070-5. [Abstract] [Full-text]
  14. Effects of unconditioned and conditioned social defeat on alcohol self-administration and reinstatement of alcohol seeking in rats.
    Psychopharmacology (Berl), 183(3): 341-9. [Abstract] [Full-text]
  15. Intense cocaine self-administration after episodic social defeat stress, but not after aggressive behavior: dissociation from corticosterone activation.
    Psychopharmacology (Berl), 183(3): 331-40. [Abstract] [Full-text]
  16. Dramatic synergistic anticancer effect of clinically achievable doses of lovastatin and troglitazone.
    Int J Cancer, 118(3): 773-9. [Abstract] [Full-text]
  17. Dextran-spermine-based polyplexes--evaluation of transgene expression and of local and systemic toxicity in mice.
    Biomaterials, 27(8): 1636-45. [Abstract] [Full-text]
  18. The impact of proteinase-induced matrix degradation on the release of VEGF from heparinized collagen matrices.
    Biomaterials, 27(8): 1608-16. [Abstract] [Full-text]
  19. Galactose-PEG dual conjugation of beta-(1-->3)-D-glucan schizophyllan for antisense oligonucleotides delivery to enhance the cellular uptake.
    Biomaterials, 27(8): 1626-35. [Abstract] [Full-text]
  20. Controlled release of bioactive TGF-beta 1 from microspheres embedded within biodegradable hydrogels.
    Biomaterials, 27(8): 1579-85. [Abstract] [Full-text]
  21. Glucose-responsive UV polymerised dextran-concanavalin A acrylic derivatised mixtures for closed-loop insulin delivery.
    Biomaterials, 27(8): 1586-97. [Abstract] [Full-text]
  22. Sequential combination of paclitaxel-carboplatin and paclitaxel-liposomal doxorubicin as a first-line treatment in patients with ovarian cancer. A multicenter phase II trial.
    Oncology, 69(4): 348-53. [Abstract] [Full-text]
  23. A phase II study of the docetaxel-ifosfamide-carboplatin combination in advanced non-small-cell lung cancer.
    Oncology, 69(4): 333-41. [Abstract] [Full-text]
  24. Paclitaxel, carboplatin and gemcitabine combination as induction chemotherapy for stage IIIA N2 bulky non-small cell lung cancer.
    Oncology, 69(4): 295-300. [Abstract] [Full-text]
  25. Combination chemotherapy in advanced small bowel adenocarcinoma.
    Oncology, 69(4): 290-4. [Abstract] [Full-text]
  26. An alternating regimen of irinotecan/ 5-fluorouracil/folinic acid and oxaliplatin/ 5-fluorouracil/folinic acid in metastatic colorectal cancer: a Phase II trial.
    Oncology, 69(4): 283-9. [Abstract] [Full-text]
  27. Present status and perspectives in the treatment of hormone-refractory prostate cancer.
    Oncology, 69(4): 273-82. [Abstract] [Full-text]
  28. Rationale for individualized therapy in Sinonasal Teratocarcinosarcoma (SNTC): case report.
    Onkologie, 28(12): 653-6. [Abstract] [Full-text]
  29. Docetaxel and cisplatin as first-line treatment for patients with metastatic esophageal cancer: a pilot study.
    Onkologie, 28(12): 647-50. [Abstract] [Full-text]
  30. Prescription pattern of aromatase inhibitors in the adjuvant setting in Germany--final results of a survey among german breast cancer specialists.
    Onkologie, 28(12): 639-44. [Abstract] [Full-text]
  31. Relation of time spent in an encounter with the use of antibiotics in pediatric office visits for viral respiratory infections.
    Arch Pediatr Adolesc Med, 159(12): 1145-9. [Abstract] [Full-text]
  32. Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial.
    J Natl Cancer Inst, 97(23): 1724-33. [Abstract] [Full-text]
  33. Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation.
    JAMA, 294(21): 2703-11. [Abstract] [Full-text]
  34. Association between cellular human immunodeficiency virus DNA level and immunological parameters in patients with undetectable plasma viremia level during highly active antiretroviral therapy.
    J Clin Microbiol, 43(12): 6183-5. [Abstract] [Full-text]
  35. Rerouting lipoprotein nanoparticles to selected alternate receptors for the targeted delivery of cancer diagnostic and therapeutic agents.
    Proc Natl Acad Sci U S A, 102(49): 17757-62. [Abstract] [Full-text]
  36. Finding new tricks for old drugs: an efficient route for public-sector drug discovery.
    Nat Rev Drug Discov, 4(12): 1005-14. [Abstract] [Full-text]
  37. Regression of invasive conjunctival squamous carcinoma in an HIV-positive patient on antiretroviral therapy.
    Int J STD AIDS, 16(12): 782-3. [Abstract] [Full-text]
  38. Surgical treatment of varicocele by a subinguinal approach combined with antegrade intraoperative sclerotherapy of venous vessels.
    BJU Int, 97(1): 142-5. [Abstract] [Full-text]
  39. Complete long-term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancer.
    BJU Int, 97(1): 42-7. [Abstract] [Full-text]
  40. Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group.
    J Clin Oncol, 23(35): 9001-7. [Abstract] [Full-text]
  41. Low-dose outpatient chemobiotherapy with temozolomide, granulocyte-macrophage colony stimulating factor, interferon-alpha2b, and recombinant interleukin-2 for the treatment of metastatic melanoma.
    J Clin Oncol, 23(35): 8992-9000. [Abstract] [Full-text]
  42. Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a phase II trial.
    Cancer Chemother Pharmacol, 57(2): 185-90. [Abstract] [Full-text]
  43. Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients.
    J Clin Oncol, 23(35): 8950-8. [Abstract] [Full-text]
  44. Combination of topotecan and cisplatin in relapsed patients with small cell lung cancer: a phase II study of the hellenic cooperative oncology group (HeCOG).
    Cancer Chemother Pharmacol, 57(2): 207-12. [Abstract] [Full-text]
  45. Toxicity and tissue distribution of magnetic nanoparticles in mice.
    Toxicol Sci, 89(1): 338-47. [Abstract] [Full-text]
  46. Ultrasound-guided foam sclerotherapy combined with sapheno-femoral ligation compared to surgical treatment of varicose veins: early results of a randomised controlled trial.
    Eur J Vasc Endovasc Surg, 31(1): 93-100. [Abstract] [Full-text]
  47. Continuous infusion intermediate-dose cytarabine, mitoxantrone, plus etoposide for refractory or early relapsed acute myelogenous leukemia.
    Leuk Res, 30(2): 204-10. [Abstract] [Full-text]
  48. Treatment of retinal angiomatous proliferation in age-related macular degeneration: a series of 104 cases of retinal angiomatous proliferation.
    Arch Ophthalmol, 123(12): 1644-50. [Abstract] [Full-text]
  49. The role of preoperative prophylactic antibiotic administration in periapical endodontic surgery: a randomized, prospective double-blind placebo-controlled study.
    Int Endod J, 38(12): 877-81. [Abstract] [Full-text]
  50. Calcium phosphate cements: competitive drug carriers for the musculoskeletal system?
    Biomaterials, 27(10): 2171-7. [Abstract] [Full-text]
  51. Highly effective and slow-biodegradable network-type cationic gene delivery polymer: small library-like approach synthesis and characterization.
    Biomaterials, 27(10): 2292-301. [Abstract] [Full-text]
  52. In vitro and in vivo studies on vitamin E TPGS-emulsified poly(D,L-lactic-co-glycolic acid) nanoparticles for paclitaxel formulation.
    Biomaterials, 27(10): 2285-91. [Abstract] [Full-text]
  53. Polymeric nanoparticle preparation that eradicates tumors.
    Nano Lett, 5(12): 2552-6. [Abstract] [Full-text]
  54. Nanotechnology-based photodynamic therapy for neovascular disease using a supramolecular nanocarrier loaded with a dendritic photosensitizer.
    Nano Lett, 5(12): 2426-31. [Abstract] [Full-text]
  55. Phase II study of high-dose chemotherapy before radiation in children with newly diagnosed high-grade astrocytoma: final analysis of Children's Cancer Group Study 9933.
    Cancer, 104(12): 2862-71. [Abstract] [Full-text]
  56. Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma.
    Cancer, 104(12): 2753-8. [Abstract] [Full-text]
  57. Phase II study of weekly irinotecan plus capecitabine for chemotherapy-naive patients with advanced nonsmall cell lung carcinoma.
    Cancer, 104(12): 2759-65. [Abstract] [Full-text]
  58. L-asparaginase as a marker of chemotherapy dose modification in children with acute lymphoblastic leukemia.
    Cancer, 104(12): 2858-61. [Abstract] [Full-text]
  59. Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326).
    Cancer, 104(12): 2766-74. [Abstract] [Full-text]
  60. The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia.
    Cancer, 104(12): 2743-52. [Abstract] [Full-text]
  61. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study.
    Cancer, 104(12): 2822-9. [Abstract] [Full-text]
  62. Estimating late adverse events using competing risks after autologous stem-cell transplantation in aggressive non-Hodgkin lymphoma patients.
    Cancer, 104(12): 2735-42. [Abstract] [Full-text]
  63. A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia: the Japan Adult Leukemia Study Group AML 97 Study.
    Cancer, 104(12): 2726-34. [Abstract] [Full-text]
  64. Does maintenance/consolidation chemotherapy have a role in the management of small cell lung cancer (SCLC)? A metaanalysis of the published controlled trials.
    Cancer, 104(12): 2650-7. [Abstract] [Full-text]
  65. Influence of antiinflammatory drugs (methylprednisolone and diclofenac sodium) on experimental pleurodesis induced by silver nitrate or talc.
    Chest, 128(6): 4041-5. [Abstract] [Full-text]
  66. A rationale for combination therapy in risk factor management: a mechanistic perspective.
    Am J Med, 118: 54-61. [Abstract] [Full-text]
  67. Association between fluid intake and weight loss during the first ten days of life and risk of bronchopulmonary dysplasia in extremely low birth weight infants.
    J Pediatr, 147(6): 786-90. [Abstract] [Full-text]
  68. A randomized controlled trial of fluid supplementation in term neonates with severe hyperbilirubinemia.
    J Pediatr, 147(6): 781-5. [Abstract] [Full-text]
  69. Potential medication dosing errors in outpatient pediatrics.
    J Pediatr, 147(6): 761-7. [Abstract] [Full-text]
  70. Effect of fluid loading with saline or colloids on pulmonary permeability, oedema and lung injury score after cardiac and major vascular surgery.
    Br J Anaesth, 96(1): 21-30. [Abstract] [Full-text]
  71. Chemoprevention of colorectal cancer.
    Dis Colon Rectum, 49(1): 113-24; discussion 124-5. [Abstract] [Full-text]
  72. Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects.
    Clin Cancer Res, 11(24): 8773-81. [Abstract] [Full-text]
  73. Phase I and pharmacokinetic study of sequences of the rebeccamycin analogue NSC 655649 and cisplatin in patients with advanced solid tumors.
    Clin Cancer Res, 11(24): 8728-36. [Abstract] [Full-text]
  74. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy.
    Clin Cancer Res, 11(24): 8715-21. [Abstract] [Full-text]
  75. Morphologic alterations associated with mechanical bowel preparation before elective colorectal surgery: a randomized trial.
    Dis Colon Rectum, 49(1): 109-12. [Abstract] [Full-text]
  76. Pretreatment with simvastatin reduces lung injury related to intestinal ischemia-reperfusion in rats.
    Anesth Analg, 102(1): 225-32. [Abstract] [Full-text]
  77. An iontophoretic fentanyl patient-activated analgesic delivery system for postoperative pain: a double-blind, placebo-controlled trial.
    Anesth Analg, 102(1): 188-94. [Abstract] [Full-text]
  78. The impact of the Canadian Hypertension Education Program on antihypertensive prescribing trends.
    Hypertension, 47(1): 22-8. [Abstract] [Full-text]
  79. Synergistic antileukemic interactions between 2-medroxyestradiol (2-ME) and histone deacetylase inhibitors involve Akt down-regulation and oxidative stress.
    Blood, 107(1): 241-9. [Abstract] [Full-text]
  80. A pilot study on the safety of combining chrysin, a non-absorbable inducer of UGT1A1, and irinotecan (CPT-11) to treat metastatic colorectal cancer.
    Cancer Chemother Pharmacol, 57(3): 309-16. [Abstract] [Full-text]
  81. Antithrombotic therapy in atrial fibrillation.
    Clin Geriatr Med, 22(1): 155-66, x. [Abstract] [Full-text]
  82. Antithrombotic and thrombolytic therapy for ischemic stroke.
    Clin Geriatr Med, 22(1): 135-54, ix-x. [Abstract] [Full-text]
  83. TP53 and P21 polymorphisms: response to cisplatinum/paclitaxel-based chemotherapy in ovarian cancer.
    Biochem Biophys Res Commun, 340(1): 256-62. [Abstract] [Full-text]
  84. Postmenopausal hormone therapy and breast cancer risk: the Multiethnic Cohort.
    Int J Cancer, 118(5): 1285-91. [Abstract] [Full-text]
  85. Obesity, hormone therapy, estrogen metabolism and risk of postmenopausal breast cancer.
    Int J Cancer, 118(5): 1292-301. [Abstract] [Full-text]
  86. Drug/device combinations for local drug therapies and infection prophylaxis.
    Biomaterials, 27(11): 2450-67. [Abstract] [Full-text]
  87. Delivery of basic fibroblast growth factor (bFGF) from photoresponsive hydrogel scaffolds.
    Biomaterials, 27(11): 2468-76. [Abstract] [Full-text]
  88. Systematic review and meta-analysis of the effectiveness of antibiotic prophylaxis in prevention of wound infection after mesh repair of abdominal wall hernia.
    Br J Surg, 93(1): 5-10. [Abstract] [Full-text]
  89. Rescue angioplasty after failed thrombolytic therapy for acute myocardial infarction.
    N Engl J Med, 353(26): 2758-68. [Abstract] [Full-text]
Place a permanent text-link or advertisement here.

© 2004-2012 Chemotherapy Research Today. All Rights Reserved.



Chemotherapy Research Today Archive:

Volume 1 (2004)
  Issue 1 (November)
  Issue 2 (December)

Volume 2 (2005)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 3 (2006)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 4 (2007)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 5 (2008)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 6 (2009)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 7 (2010)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 8 (2011)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 9 (2012)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)



Chemotherapy Books

The Cancer Chemotherapy Handbook (6th Edition)

The Cancer Chemotherapy Handbook (6th Edition)